Lizoril, tablets 10 mg 28 pcs

Lizoril is an ACE inhibitor. Inhibits the formation of angiotensin II from angeotensin I. Reduces angeotensin II leads to a direct reduction of aldosterone release. Reduces bradykinin degradation and increases prostaglandin synthesis. Reduces total peripheral vascular resistance, BP, preload, pulmonary capillary pressure, causes an increase in cardiac output and increases myocardial tolerance to exercise in patients with heart failure. Dilates arteries more than veins. Some effects are explained by the effect on tissue renin-angiotensin systems.

Long-term use reduces myocardial hypertrophy and arterial resistive walls. It improves the blood supply to the ischemic myocardium. ACE inhibitors prolong life expectancy in patients with heart failure and slow the progression of left ventricular dysfunction in patients who have had myocardial infarction without clinical manifestations of heart failure.

The onset of action is in 1 hour. The maximum effect is determined after 6-7 hours, the duration – 24 hours. In case of arterial hypertension the effect is observed within the first days after the treatment start; the stable action develops within 1-2 months.

Pharmacokinetics

The drug bioavailability is 25-50%, poorly bound to blood plasma proteins. Cmax in blood serum is reached after 7 hours. Absorption is not influenced by food intake.

Permeability through the GEB and the placental barrier is low.

Lisoryl is not metabolized and is excreted unchanged in the urine. Most of it is excreted during the initial phase (effective T1/2 is 12 hours), followed by the terminal distant phase (T1/2 about 30 hours).

Indications

Arterial hypertension, chronic heart failure.

Active ingredient

Composition

Active ingredient:

lisinopril 10 mg.

Associates:

starch,

mannitol,

dicalcium phosphate dihydrate,

Magnesium stearate,

Red iron oxide dye.

.

How to take, the dosage

Lizoril is taken orally.

In arterial hypertension: initial dose is 5 mg once daily, if necessary – up to 40 mg/day. In congestive heart failure: initial dose is 2.5 mg and if necessary – up to 20 mg/day.

In case of hydro-electrolyte balance disorders, diuretic therapy of renal insufficiency and in renovascular hypertension the initial dose is 1.25 mg/day.

Interaction

Concomitant use with NSAIDs, estrogens and sympathomimetics may reduce the effectiveness of Lizoral.

Combined use with beta-blockers, calcium channel blockers, diuretics and other hypotensive agents increases the severity of the hypotensive effect of Lizoral.

Concomitant use of Lizoral with potassium-saving diuretics may cause hyperkalemia.

Lisoryl may slow the excretion of lithium from the body when co-administered with lithium preparations.

Special Instructions

Caution is exercised when prescribing the drug in patients with impaired renal function as well as in patients receiving diuretics.
In cases of allergic reactions, treatment with Lizoril should be stopped.

Control of laboratory parameters

Laboratory parameters of renal function, water-electrolyte exchange should be monitored and, if necessary, fluid and salt loss should be compensated before starting therapy with Lizoril.

While therapy, the number of white blood cells should be periodically monitored, especially in patients with autoimmune and renal diseases, as well as the potassium content in plasma.

Contraindications

Hypersensitivity to lisinopril or other ACE inhibitors; history of angioedema, including from use of ACE inhibitors, hereditary Quincke’s edema or idiopathic edema; pregnancy, lactation, age under 18 years (safety and effectiveness have not been determined).

Side effects

Nervous system and sense organs: headache, dizziness.

Gastrointestinal system disorders: nausea, vomiting, increased liver transaminase activity.

Cardiovascular system and blood (hematopoiesis, hemostasis): hypotension, tachycardia, neutro/thrombocytopenia, decrease in hemoglobin levels.

Respiratory system: dry cough, bronchitis.

Allergic reactions: Quincke’s edema, skin rash.

Others: muscle cramps, hyperkalemia, impaired renal function.

Overdose

Symptoms: arterial hypotension.

Treatment: intravenous sodium chloride isotonic solution, hemodialysis.

Similarities